Projecten
Gegevensintegratie voor de voorspelling van drug-target interacties in voor de ontwikkeling van geneesmiddelen en 'drug repositioning’ KU Leuven
Goedgekeurde geneesmiddelen hebben favoriete of gevalideerd farmacokinetische eigenschappen en toxicologische profielen, en de herpositionering van bestaande geneesmiddelen voor nieuwe indicaties kunnen potentieel dure kosten in verband met een vroeg stadium het testen van de hit verbindingen te vermijden. In de afgelopen jaren de technologische vooruitgang in de virtuele screening methoden hebben toegestaan medicinale chemici om snel te ...
Estimation of the risk of developing resistance to anti-leishmanial drugs Instituut voor Tropische Geneeskunde
Utilization of molecular resistance test results as tools to support public health efforts for improved control of rifampicin resistant tuberculosis Instituut voor Tropische Geneeskunde
Een ecosysteem bouwen voor een betere monitoring en communicatie van medicatieveiligheid in de zwangerschap en borstvoeding: gevalideerde en door de wetgever goedgekeurde workflows voor een snelle, geoptimaliseerde ontwikkeling van bewijsmateriaal KU Leuven
ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and lactation.
What do we deliver? ConcePTION aims to create a paradigm shift in how we study medication safety in pregnancy. We will establish (1) a successful, sustainable open-science based EU non-proprietary ecosystem of public and private ...
microbiome-gebaseerde biomarkers om decompensatie van levercirrose en behandelingsreacties te voorspellen KU Leuven
Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host ...
ChOLLATERAL: Genereren van een netwerk van ongunstige uitkomstroutes op cholestatische leverbeschadiging voor op mechanismen gebaseerde in-vitrotesten van chemicaliën. Vrije Universiteit Brussel
Cholestasis refers to toxic bile acid accumulation mainly in the liver and can be induced by many chemical compounds, in particular drugs. At present, drug-induced cholestatic injury (DICI) is poorly predictable and is an important reason for drug withdrawal from the market as well as a major clinical issue. A solution lies in better understanding the mechanisms of DICI. A pragmatic tool to visually and rationally capture the ...
Chromatografische micro-kolom ontwikkeling voor farmaceutische toepassingen in zebravis KU Leuven
ADME (Absorption, Distribution, Metabolism and Excretion) studies focus on the examination and prediction of drug behavior in the human body. Zebrafish present a good in vivo model for this purpose since they comply with the 3R principle of humane animal research (Replacement, Reduction and Refinement). The research group of Prof. Deirdre Cabooter recently developed a novel sample preparation and analytical method to accurately measure the ...
Een geïntegreerde interdisciplinaire benadering voor diervrije chemische en nanomateriële veiligheidsbeoordeling KU Leuven
All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The use of whole animal studies for the prediction of adverse effects in man, is problematic due to species dependent effects, high costs and a large burden to animals in terms of numbers and suffering. While there have been major improvements in human in vitro and in silico techniques, there is still a lack ...
Analytical treatment interruption in HIV positive patients with low viral reservoir to evaluate the potential of a functional cure Instituut voor Tropische Geneeskunde
antiretroviral drugs can be stopped and followed by a control of HIV. The design is original and, to our
knowledge, not yet implemented. The potential of stopping cART is indeed a new emerging question in
HIV cure trials. There is no interest from the side of pharmaceutical companies. Designing interventions
where antiretroviral ...